Digital Diagnostics™ proves reimbursement is foundational to adoption of healthcare AI at scale with evidence from LumineticsCore™ autonomous AI

CORALVILLE, IOWA April 30, 2024 – In a groundbreaking publication, the New England Journal of Medicine (NEJM-AI) published a paper authored by Michael D. Abramoff, MD, PhD, with co-authors Tinglong Dai, PhD, and James Zou, PhD, titled “Scaling Adoption of Medical AI: Reimbursement from Value-Based Care and Fee-for-Service Perspectives,” shedding light on the transformative potential of Artificial Intelligence (AI) in healthcare when all stakeholders and real world evidence support its adoption and sustainable reimbursement. The research conducted by Abramoff et al, using Digital Diagnostics’™ LumineticsCore™ as a prime example, underscores the dependency of commercial viability and real-world evidence, proving improved patient outcomes associated with integrating AI technologies in healthcare settings that have national reimbursement to support the adoption of such technology are paramount.

The paper delves into the dual lenses of value-based care and fee-for-service models, providing a comprehensive analysis of how AI-driven solutions can enhance patient outcomes, productivity, operational efficiency, and financial sustainability across diverse healthcare settings. The paper examines evidence from randomized controlled trials and other independent studies that specific medical AI can improve patient outcomes, health equity, and physician productivity and satisfaction, and drive down cost, at scale. There is also evidence that without sustainable reimbursement, not just any form of reimbursement, such benefits cannot be achieved. According to the publication:

A sustainable reimbursement model must meet the following criteria […]: ensure trust and patient benefit, by meeting foundational criteria and an ethical framework; […] ensure appropriate utilization and avoidance of overutilization; ensure financial sustainability; ensure a short path length; and allow informed deployment decisions by medical professionals, health systems, and payers through transparency in estimating financial impact.

While the challenges for achieving sustainable reimbursement can seem insurmountable, they are being overcome and Digital Diagnostics presents the core example, which can be seen through the adoption of LumineticsCore in real-world settings. LumineticsCore has examined over 90,000 patients since clearance in 2018, leading to multiple studies showing the effectiveness of autonomous AI in healthcare such as:

• A reimbursement framework for artificial intelligence in healthcare
• Determinants for scalable adoption of autonomous AI in the detection of diabetic eye disease in a diverse practice types: key best practices learned through collection of real-world data
• Foundational considerations for artificial intelligence utilizing ophthalmic images
• Identifying Ethical Considerations for Machine Learning Healthcare Applications
• Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices
• Autonomous artificial intelligence increases real-world specialist clinic productivity in a cluster-randomized trial
• Autonomous Artificial Intelligence in Diabetic Retinopathy: From Algorithm to Clinical Application

“Without sustainable reimbursement wide-spread adoption of healthcare AI wouldn’t be possible,” said Michael Abramoff, MD, PhD. “There is a ton of noise out there about AI, and we need to stop talking about it in terms of “potential”, as the scientific evidence is now in and actionable; we need to focus on adoption at scale because people’s vision and lives are at stake.”

To access the full paper follow this link: NEJM-AI, and explore an expanded list of relevant publications authored by Abramoff here.

About Digital Diagnostics Inc.

Digital Diagnostics Inc. is a pioneering AI diagnostics company on a mission to transform the quality, accessibility, equity, and affordability of global healthcare through the application of technology in the medical diagnosis and treatment process. The company, originally founded by Michael Abramoff, MD, PhD, a neuroscientist, practicing fellowship-trained retina specialist, and computer engineer, is led by him and co-founder and CEO, John Bertrand.

Digital Diagnostics is paving the way for autonomous and assistive AI technology that is free of bias to become a new standard of care, contributing to democratizing healthcare and closing care gaps. The company works closely with patient advocacy groups, provider organizations, regulators, and other quality of care and ethics-focused stakeholders to enable the adoption of healthcare AI. For more information and the latest news follow: https://digitaldiagnostics.com/